Refractory Dedifferentiated Liposarcoma
1 clinical trials · Condition
◉ Watch Refractory Dedifferentiated Liposarcoma
| Record | Firm | Date |
|---|---|---|
| Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (NCT04668300) | M.D. Anderson Cancer Center | 2020-11-26 |
Track Refractory Dedifferentiated Liposarcoma automatically
Every clearance here is in the API, with alerts when new ones post.